Title:

Spectrum of innate and adaptive immune response to SARS-CoV-2 infection across asymptomatic, mild and severe cases – a longitudinal cohort study

Rita Carsetti[1,2*], Salvatore Zaffina[3,4], Eva Piano Mortari[1#], Sara Terreri[1#], Francesco Corrente[2], Claudia Capponi[2], Patrizia Palomba[2], Mattia Mirabella[2], Simona Cascioli[5], Paolo Palange[6], Ilaria Cuccaro[6], Cinzia Milito[7], Alimuddin Zumla[8,9], Markus Maeurer[10,11], Vincenzo Camisa[3,4], Maria Rosaria Vinci[3,4], Annapaola Santoro[3,4], Eleonora Cimini[12], Luisa Marchioni[13], Emanuele Nicastri[13], Fabrizio Palmieri[13], Chiara Agrati[12], Giuseppe Ippolito[14], Ottavia Porzio[15,16], Carlo Concato[17], Andrea Onetti Muda[18], Massimiliano Raponi[4], Concetta Quintarelli[19,20], Isabella Quinti[7], Franco Locatelli[19,21]

Affiliations:

[1]B Cell Pathophysiology Unit, Immunology Research Area, Bambino Gesù Children's Hospital IRCCS, Rome, Italy;
[2]Diagnostic Immunology Unit, Department of Laboratories, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
[3]Occupational Medicine/Health Technology Assessment and Safety Research Unit, Clinical-Technological Innovations Research Area, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
[4]Health Directorate, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
[5]Research Laboratories, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
[6]Department of Public Health and infectious diseases pulmonary division, Policlinico Umberto I Hospital, Rome, Italy.
[7]Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy
[8]Center for Clinical Microbiology, Division of Infection and Immunity, University College London, London, United Kingdom
[9]NIHR Biomedical Research Centre, UCL Hospitals NHS Foundation Trust, London, United Kingdom.
[10]Champalimaud Centre, Lisbon, Portugal
[11]Med Clinic, University of Mainz, Germany
[12]Cellular Immunology Laboratory, INMI L Spallanzani, IRCCS, Rome, Italy
[13]Clinical Department, INMI L Spallanzani, IRCCS, Rome, Italy
[14]Scientific Direction, INMI L Spallanzani, IRCCS, Rome, Italy
[15]Medical Laboratory Unit, Bambino Gesù Children's Hospital, IRCCS
[16]Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy
[17]Virology Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
[18]Department of Laboratories, Bambino Gesù Children's Hospital, Rome, Italy
[19]Department of Hematology/Oncology, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
[20]Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
[21]Department of Pediatrics, Sapienza, University of Rome, Rome, Italy

Lead contact

[#]These authors contributed equally to this work.

[*]**Corresponding author**: Dr. Rita Carsetti, B Cell Pathophysiology Unit, Immunology Research Area, Diagnostic Immunology Unit, Department of Laboratories, Bambino Gesù Children Hospital, Viale di San Paolo 15, 00146 Rome, Italy Fax: +39-06-72596822 e-mail: rita.carsetti@opbg.net

Funding:

This work was founded by the RF2013-02358960 grant from the Italian Ministry of Health.

Declaration of interests

The authors declare no competing interests

Summary: The ratio between monocytes and NK may represent a prognostic marker of disease development in COVID-19. Individuals with asymptomatic SARS-CoV2 infection have a high frequency of NK cells associated to a transient IgA response to the infection

Abstract:

Background: SARS-CoV-2 is a novel coronavirus, not encountered before by humans. The wide spectrum of clinical expression of SARS-CoV-2 illness suggests that individual immune responses to SARS-CoV-2 play a crucial role in determining the clinical course after first infection.
Immunological studies have focussed on patients with moderate to severe disease, demonstrating excessive inflammation in tissues and organ damage.
We have studied the individual response to SARS-CoV-2 of asympromatic, mild and severe COVID-19 patients in order to investigate the role of innnate and adaptive immunity in determining the clinical course after first infection.
Methods: To understand the basis of the protective immune response in COVID-19, we performed a longitudinal follow-up analysis of innate and adaptive immunity in **64** adults with a spectrum of clinical presentations: (**28** healthy SARS-CoV-2-negative contacts of COVID-19 cases; **20** asymptomatic SARS-CoV-2-infected cases; **8** patients with mild COVID-19 disease and **8** cases of severe COVID-19 disease).
Results: Our data show that high frequency of NK cells and early and transient increase of specific IgA and, to a lower extent, IgG are associated to asymptomatic SARS-CoV-2 infection. By contrast, monocyte expansion and high and persistent levels of IgA and IgG, produced relatively late in the course of the infection, characterize severe disease. Modest increase of monocytes and rapidly declining antibodies are detected in mild COVID-19.
Conclusions: The importance of innate NK cells and the short-lived antibody response of asymptomatic individuals and patients with mild disease suggest that only severe COVID-19 may result in protective memory established by the adaptive immune response.

Keywords: COVID-19, antibodies, NK, monocytes, adaptive immune system, innate immune response.

Abbreviations: SARS-CoV-2: Severe Adult Respiratory Syndrome-Coronavirus-2, COVID-19: Coronavirus Disease 2019, ACE2: Angiotensin Converting Enzyme-2, MBCs: memory B cells, MLR: Monocyte-Lymphocyte ratio, NLR: Neutrophil-Lymphocyte ratio, MNKR: Monocyte-NK ratio, IFN-γ: interferon-gamma, HLH: Hemophagocytic Lymphohistiocytosis, TGF-beta: transforming growth factor-beta

101 **Introduction**

102 SARS-CoV-2 is a novel coronavirus, not encountered before by humans. Thus, everyone is
103 susceptible to infection as the virus rapidly spreads in the current Coronavirus disease 2019
104 (COVID-19) pandemic. A wide spectrum of clinical expression of SARS-CoV-2 infection occurs,
105 ranging from asymptomatic to mild upper respiratory tract illness, or moderate to severe disease
106 with respiratory distress and multi-organ failure requiring intensive care and organ support[1]. This
107 variability of disease severity suggests that the individual immune responses to SARS-CoV-2 play a
108 crucial role in determining the clinical course after first infection. Understanding the pathogenesis
109 of COVID-19 disease requires in-depth study of underlying immune responses[2].

110 In COVID-19, lymphopenia is common and correlates with severity of clinical disease[3].
111 Lymphopenia is caused by the reduction of both $CD4^+$ and $CD8^+$ T cells. Surviving T cells are
112 functionally exhausted and reduced T-cell count predicts an unfavourable clinical course[4]. T cells
113 able to react to SARS-CoV-2 peptides can be demonstrated in healthy individuals, probably
114 because of a cross-reactivity with previous infections by other coronaviruses and are expanded in
115 individuals convalescent from COVID-19[5].

116 Antibodies to SARS-CoV-2 are produced in large amounts in patients with severe disease, two-
117 three weeks after the occurrence of first symptoms[6]. The role of antibodies in viral elimination is
118 supported by the successful use of convalescent plasma in patients with severe COVID-19[7].
119 Neutralizing antibodies are directed against the Receptor Binding Domain contained in the S1
120 subunit of the Spike protein[8,9]. Whilst immune responses to novel antigens encountered for the
121 first time, are first dominated by antibodies of IgM isotype, followed by IgG[10], the kinetics and
122 protective or deleterious nature of the antibody responses to SARS-CoV-2 remains to be defined. A
123 recent study indicated that the IgA response to SARS-CoV-2 may be rapid, strong and
124 persistent[11]. The observation that patients with severe COVID-19 disease have very high
125 antibody levels led to the suggestion that antibodies to SARS-CoV-2 may be damaging or
126 ineffective rather than protective[12,13], as was reported from very sick patients with Middle East
127 respiratory syndrome (MERS)[14].

128 Whilst immunological studies to date have focussed on patients with moderate to severe COVID-19
129 disease[15], studies from across the clinical spectrum are required to better understand immune
130 responses to SARS-CoV-2 infection. We performed a longitudinal study of innate and adaptive
131 immune populations in the peripheral blood of adults with asymptomatic SARS-CoV-2 infection,
132 and those with mild and severe COVID-19 disease and their healthy contacts.

133

134 **Methods:**

135

136 **Ethical approval**

137 Ethical approval was obtained from the Medical Research and Ethics Committee at Sapienza,
138 University of Rome. The study was performed in accordance with the Good Clinical Practice
139 guidelines, the International Conference on Harmonization guidelines, and the most recent version
140 of the Declaration of Helsinki.
141 Study sites: 1) Bambino Gesù Children Hospital 2) Policlinico Umberto I Hospital.
142
143 **Patients**.
144 Sixty-four adult patients were enrolled in the study:
145 **28** healthy controls: Contacts of SARS-CoV-2 confirmed cases who were confirmed as negative by
146 qPCR and were studied as control group;
147 **20** asymptomatic cases (defined as contacts of COVID-19 cases but with no symptoms during the
148 duration of study time but tested positive for viral RNA). Asymptomatic patients were quarantined
149 and monitored for 14 days, and quarantine ended when two consecutive nasopharyngeal swabs
150 showed negative results[16];
151 **8** patients with Mild COVID-19 disease (defined by positive SARS-CoV-2 nasopharyngeal swab
152 qPCR test, with symptoms such as fever, myalgia and fatigue without obvious chest HRCT findings
153 for COVID-19 did not require hospitalization);
154 **8** cases of Severe COVID-19 disease from Policlinico Umberto I Hospital who were hospitalized
155 for respiratory disease with bilateral lung infiltrates at HRCT highly suggestive of COVID-19
156 interstitial pneumonia, and P/F ≥ 300 mmHg (defined as the ratio of arterial oxygen tension [PaO2]
157 to inspiratory oxygen fraction [FiO2]).
158
159 **Clinical Characteristics.**
160 Severe adult COVID-19 patients (8 patients) were older (mean age, 65 years, range 30-90) than
161 mild-symptoms adult COVID-19 patients (8 patients, mean age, 55.2 years, range 48-64). Sex ratio
162 with a prevalence of male patients was similar in the two groups (severe: M/F 6/2; mild: M/F 5/3).
163 During the study period, disease activity was regularly assessed, and COVID-19 patients continued
164 their therapies according to the standard of care. Four out of eight severe cases were treated with
165 anti-IL-6R monoclonal antibody (tocilizumab). All hospitalized COVID-19 patients were
166 discharged and none died. Twenty patients, grouped as SARS-CoV-2 asymptomatic patients had a
167 mean age of 40.4 (range 27-64) and a sex ratio (M/F) equal to 4/16. Twenty-eight contacts SARS-
168 CoV-2-negative had a mean age of 40.8 years (range 27-68) and an 8/20 M/F sex ratio
169 (**Supplementary Table 1**).
170
171 **Flow-cytometry and antibodies**

172 Four leukocyte profiling panels computing 7- to 9-surface marker antigens for monitoring the major
173 leukocyte subsets as well as characteristics of T-cell, B-cell, monocytes and NK cells subsets were
174 designed (**Supplementary Table S2**). Results of immune-profile of analyzed patients are reported
175 in **Supplementary Table 3-10**.
176 1 ml of total blood (EDTA) was incubated with the lysing solution Pharm Lyse (BD) to lyse red
177 blood cells. Then, cells were divided in four equal aliquots and stained with the appropriate
178 combination of fluorochrome-conjugated antibodies (**Table E1**) to identify immune cell subsets
179 according to standard techniques. For the staining of **Figure E7**, heparinized PBMCs of three
180 healthy donors were isolated by Ficoll Paque™ Plus 206 (Amersham Pharmacia Biotech) density-
181 gradient centrifugation. Cells were then stained with antibodies against CD19, CD24, CD27, CD38,
182 IgM, IgG, IgA and IgD (**Supplementary Table 1**). Cells were acquired on a BD FACSLyric™
183 (BD Biosciences). Data were analyzed with FlowJo ver. 10 (Treestar). Dead cells were excluded
184 from analysis by side/forward scatter gating.
185
186 **Serum samples**
187 Sera were obtained from the sixty-four patients included in the study. Some of the samples were
188 collected at different time points. Included in this study were 151 serum samples obtained from
189 subjects with available clinical records. In particular: forty-four sera from SARS-Cov-2 negative
190 contacts, fifty-one from SARS-Cov-2 asymptomatic patients, forty-one from COVID-19 mild
191 patients and fifteen from COVID-19 severe patients. All sera were kept on ice after collection and
192 then stored at -80°C.
193
194 **Serological assays**
195 The Euroimmun Anti-SARS-CoV-2 ELISA IgG and IgA assays (Euroimmun, Luebeck, Germany)
196 were performed on serum samples according to the manufacturer's instructions. The recommended
197 serum samples dilutions used were 1:100; in samples in which the IgA or IgG quantity was not
198 detectable (overflow), we used 1:1000, 1:3000, 1:6000, 1:25000 dilutions. These ELISA assays
199 provide a semi-quantitative *in vitro* determination of human antibodies of the immunoglobulin
200 classes IgG and IgA against the SARS-CoV-2. The microplate wells are coated with recombinant
201 S1 structural protein. The results are evaluated by calculation of the ratio between the extinction of
202 samples and the extinction of the calibrator. The ratio interpretation was as follows: <0.8 =
203 negative, ≥ 0.8 to < 1.1 = borderline, ≥ 1.1 = positive.
204
205 **Statistical analysis**

206 We performed the unpaired, two-tailed Mann-Whitney *U*-tests. A $p \leq 0.05$ was considered to be
207 statistically significant.
208
209 **Results:**
210 *Innate immunity*
211 The PBMCs of patients with asymptomatic infection, mild and severe disease and their healthy
212 contacts were compared. We correlated the immunological findings with the clinical course and
213 studied the dynamic changes of cells of innate and adaptive immune response.
214 By flow-cytometry, we confirmed that the Monocyte-Lymphocyte ratio (MLR) increases in
215 advanced COVID-19 cases, when T cells, normally representing the major lymphocyte population
216 in the peripheral blood, are reduced[15] (**Figure 1a and b**). Previous studies indicated that
217 neutrophils and macrophages infiltrate the lungs and are expanded in the peripheral blood of
218 Intensive Care Unit (ICU)-admitted patients[17]. The increase of circulating neutrophils and
219 monocytes, along with lymphopenia, explains why the Neutrophil-Lymphocyte ratio (NLR) and
220 MLR are significantly higher in patients with severe COVID-19 disease.
221 T-cell frequencies are preserved in asymptomatic individuals and in patients with mild disease.
222 Thus, in order to investigate whether other lymphocyte populations change in relationship to
223 monocytes, we excluded T cells from the first analysis (**Figure 1c and Supplementary Figure 1**).
224 Besides B cells discussed below, the $CD3^-$ gate includes monocytes that can be distinguished by
225 their larger size measured by the high FCS, and NK cells. NK cells express the markers CD7
226 (**Figure 1c**) and CD56 **(Supplementary Figure 1s**).

227 We found that the frequency of NK cells was reduced and that of monocytes increased in patients
228 with severe COVID-19. Similar alterations of NK and monocytes were observed in the group of
229 patients with mild disease (**Figure 1d and e**). For this reason, we calculated the Monocyte to NK
230 ratio (MNKR), which appeared to be altered not only in the severe cases, but also in patients with
231 mild disease (**Figure 1e**). The differences between asymptomatic, mild and severe COVID-19
232 remained significant when we included all the samples collected from the patients at different time
233 points (**Figure 2a**), suggesting that the reduction of NK and monocytes and the high MNKR was
234 not an incidental finding observed in a particular moment of the infection, but rather is a
235 characteristic of the disease. Each individual maintained his typical NK and Monocyte frequency
236 throughout the time of follow-up (**Figure 2b**). We confirmed the importance of the frequency of
237 NK cells by the retrospective analysis of 77 patients with severe COVID-19. Cases who did not
238 need ICU treatment had a significantly higher number of NK cells ($CD56^+$ cells calculated in $CD3^-$
239 lympho-monocyte gate) than ICU patients (**Figure 2c**). In addition, the percentage of NK cells

240 increased in those individuals who recovered from severe disease, whereas it remained low in
241 patients with fatal COVID-19 (**Figure 2d**). These results are corroborated by the observation that
242 ICU patients had lower perforin$^+$ NK cells compared to non-ICU patients[18].

243 CD16 expression allows to differentiate three types of CD14$^+$ monocytes (**Supplementary Figure**
244 **2a and 3**) in the peripheral blood, reflecting sequential stages of maturation and distinct
245 functions[19,20]. Classical monocytes are the precursors of the other types and play an important
246 role in the response to pathogens and in the resolution of inflammation. Intermediate monocytes
247 secrete inflammatory cytokines in response to Toll-Like Receptor (TLR) stimulation and expand in
248 the blood of patients with severe infections[21]. Non-classical monocytes contribute to the
249 resolution of inflammation and maintaining vascular homeostasis and endothelial integrity[22].
250 We found that non-classical monocytes were significantly reduced in patients with severe COVID-
251 19 when compared to SARS-CoV-2 negative contacts, SARS-CoV-2 positive asymptomatic and
252 also mild COVID-19 disease patients (**Supplementary Figure 2b**). Intermediate monocytes were
253 increased in the severe cases, but the difference reached statistically significance only when we
254 considered all samples collected for the study (**Supplementary Figure 2c**). As the progression
255 from the classical to intermediate stage is a dynamic step driven by infectious triggers[19], we
256 compared the monocyte phenotype in the same patients at different time points during the course of
257 the disease. Whereas intermediate monocytes were rare in the blood of contacts, asymptomatic and
258 mild disease patients at all time points, transient increases were observed in patients experiencing
259 severe disease (**Supplementary Figure 2d**).
260 In summary, we found that the MNKR reflects the clinical phenotype of the disease. Contact and
261 asymptomatic patients had either higher representation of NK cells or a similar frequency of NK
262 and monocytes (ratio around 1). The ratio was >1 in patients with mild disease and reached higher
263 values in the severe cases. Thus, the equilibrium between two cell types of the innate immune
264 system may play a role in the control of SARS-CoV-2 infection. Prevalence of NK cells is
265 associated to asymptomatic infection, while increased frequency of monocytes to severe disease.
266

267 *Adaptive immunity*

268 T and B cells play key roles in response to viral infections. CD8$^+$ T lymphocytes are crucial for the
269 limitation of viral spread through their cytotoxic function. CD4$^+$ T cells are indispensable for the
270 expansion of CD8$^+$ T cells and the generation of CD8$^+$ memory T cells[23]. In addition, CD4$^+$ T
271 cells are necessary for the germinal centre (GC) response and the production of memory B cells
272 (MBCs) and plasma cells[24].
273 A recent study reported that 82.1% of the severe COVID-19 cases had low circulating lymphocyte
274 counts because of the reduced frequency of CD3$^+$ T cells, both of CD4 and CD8 type[25]. In severe

275 COVID-19, not only the number of $CD8^+$ T cell declines but also their function is impaired, in
276 association with the increase of pro-inflammatory cytokines[18].
277 We observed an increase of activated, HLA-DR^+ CD4 T cells in patients with mild and severe
278 disease (**Figure 3a and b**). By contrast, HLA-DR^+ CD8 T cells were increased only in patients with
279 severe COVID-19 (**Figure 3 a and b**). This finding was confirmed when we included all samples in
280 the analysis (**Supplementary Figure 4**).
281 In a separate staining, we identified *naïve* and memory T cells, including central, effector and
282 terminally differentiated (TEMRA) memory T cells (**gating strategy in supplementary Figure 5**).
283 In the $CD4^+$ population of patients with mild and severe COVID-19, we found a reduction of recent
284 thymic emigrants ($CD45RA^+CCR7^+CD31^+$) and a consequent relative increase of $CD31^-$
285 $CD45RA^+CCR7^+$ T cells. No other significant modifications of the cell distribution were observed
286 and confirmed by the analysis of all patient samples (**Supplementary Figure 6**). In the $CD8^+$ T-cell
287 population, the most important change was the reduction of $CD45RA^+CCR7^+$ T cells, with modest
288 alterations of the $CD31^+$ and $CD31^-$ cell frequency. Total effector memory $CD8^+$ T cells were
289 increased only in asymptomatic cases (**Figure 4 and Supplementary Figure 6**), whereas in severe
290 disease, $CD8^+$ EM2 were increased and EM4 decreased. As reported before[5,26] $CD8^+$ TEMRA
291 were increased in patients with advanced disease (**Figure 4b and Supplementary Figure 6**).
292 Our data indicate that the circulating pool of T cells is not dramatically changed by SARS-COV-2
293 infection in asymptomatic individuals. In mild and severe cases, $CD4^+$ T cells express HLA-DR.
294 Activation of $CD8^+$ T cells could be only demonstrated in the severe cases and was associated to the
295 increase of highly cytotoxic EM2[27] and to the accumulation of exhausted TEMRA.
296 We identified the different B-cell populations in the peripheral blood by staining with a
297 combination of antibodies able to distinguish transitional, naïve, memory, atypical MBCs and
298 plasmablasts (**Figure 5a**). In the $CD27^+$ MBCs population, we separately analysed IgM^+ and
299 switched MBCs. The latter include IgG^+ MBCs and IgG^- MBCs. Most of the IgG^- B cells
300 correspond to IgA-expressing memory B and in minimal part to MBCs without detectable surface
301 immunoglobulin (**Supplementary Figure 7**). The most significant findings were the reduction of
302 total B cells and the increase of plasmablasts in the severe cases (**Figure 5b**). Among MBCs, we
303 found an increase of IgM^+ and a reduction of switched MBCs in asymptomatic and mild cases. In
304 patients with severe disease, IgM^+ MBCs were reduced and switched MBCs increased (**Figure 5c**),
305 with a significant expansion of the IgG^- switched population. IgG^+ MBCs were reduced in the blood
306 of patients with mild disease (**Figure 5d**). For this reason, the ratio between IgG^+ and IgG^- switched
307 MBCs, that is >1 in the SARS-Cov-2 negative contacts and asymptomatic individuals, is
308 significantly lower in patients with mild and severe COVID-19 indicating the expansion of MBCs

309 that do not express IgG and most probably express IgA (**Supplementary Figure 7**). All the
310 findings were confirmed by the cumulative analysis of all samples (**Supplementary Figure 8**).
311 B cells fight viruses by producing antibodies when they differentiate into circulating plasmablasts
312 or tissue–resident plasma cells. The final stages of differentiation can be reached by B cells in the
313 GCs, where either *naïve* or IgM^+ MBCs[28,29] acquire somatic mutations and are selected for their
314 increased affinity to the stimulating antigen[24]. T- and GC-independent antibody production is
315 efficiently and rapidly triggered by TLR-mediated stimulation of MBCs[30,31].
316 IgG and IgA antibodies directed against the S1 domain of the SARS-CoV-2 Spike protein were
317 measured in the entire study cohort. We found that antibodies are produced by all COVID-19
318 patients and also by SARS-CoV-2 positive asymptomatic individuals, with higher levels of IgG and
319 IgA being detected in the serum of patients with severe disease (**Figure 6a**) as reported
320 before[13,32].
321 In order to study the dynamic nature of the antibody response, we analysed its kinetics in 9
322 asymptomatic individuals, 8 patients with mild and 4 with severe disease. We found that
323 asymptomatic patients secrete high levels of S1-specific IgA early after diagnosis. IgA rapidly
324 declines and becomes undetectable after 5-7 weeks. IgG is low at most time points (**Figure 6b**).
325 The response of patients with mild disease has different kinetics, with IgG and IgA increasing later
326 and remaining relatively low, with few exceptions (**Figure 6c**). IgG and IgA are produced late in
327 patients with severe COVID-19, but in higher amounts[13,32]. IgA was always more abundant than
328 IgG (**Figure 6d**).
329 Antigen-specific IgA and IgG were undetectable in 2 patients with severe disease and in 1 with
330 mild disease. The inability to produce antibodies in isolated cases with severe and mild disease may
331 be due to individual genetic variation or age: pt34 was 83-year-old with a severe disease (1 single
332 sample was obtained), and pt14 was young but had a rapidly evolving severe disease (3 samples
333 were analysed at different time points), that improved with treatment. Pt11 (data not shown) with
334 mild disease was otherwise healthy, but had neurological symptoms and a positive nasopharyngeal
335 swab PCR lasting for 8 weeks (6 samples were evaluated).
336 The most interesting and intriguing aspect of the immunoglobulin study was the observation that
337 among the samples of asymptomatic individuals 17% (9 of 53 samples) were negative for IgG and
338 22.6% (12 of 53) were negative for IgA. This high percentage of negative samples cannot be
339 explained by individual variations. As serum antibody titers rapidly decline in asymptomatic
340 patients (**Figure 6b**), we correlated the level of SARS-CoV-2 specific antibody to the time from the
341 first positive nasopharyngeal swab. We found that six serum samples with non-detectable specific
342 IgA and IgG had been obtained from individuals diagnosed as positive for SARS-CoV-2 eight to
343 sixteen weeks prior to serum analysis (**Figure 6e-empty circles**). Of the other asymptomatic

individuals, we had multiple samples. In one case, IgA and IgG were undetectable in the first sample obtained on same day of the first positive swab, but IgA and IgG rapidly increased in the second sample at day 18 after the first positive swab. The other values below the detection threshold refer to the late stages of the antibody kinetics from individuals with a previously detectable IgG and IgA response.

In summary, we observed that asymptomatic patients have an early serum IgA response that may be able to rapidly control SARS-CoV-2 in the respiratory mucosa, thus preventing a full adaptive immune response. The lack of the early IgA burst may result in a longer persistence of the virus and induction of the GC response in the local lymphoid tissue. The adaptive response becomes stronger and probably geographically diffuse in the lymphoid tissue draining the severely damaged respiratory epithelium in patients with severe disease.

Discussion

Individual immune responses play an important role in determining the clinical course of SARS-CoV-2 infection in adults. Since the adaptive response requires time to build up after first encounter with a novel virus, the first line immediate responders are NK cells and natural antibodies, key components of innate immune system [33–37].

NK cells kill infected cells and produce IFN-ɣ with antiviral function[38]. 'Natural antibodies' are antibodies that have a protective role in the early phases of the response independent of any previous encounter with antigens [39–41]. In humans, natural antibodies are produced by innate IgM^+ MBCs[31]. These antibodies, not yet been shaped by antigenic selection, carry few somatic mutations[28] and have broad reactivity[42]. We recently suggested that these antibodies might explain why most pediatric cases with laboratory-confirmed SARS-CoV-2 infection have either no or mild symptoms and recover within 1–2 weeks[43]. Cross-reactive antibodies found in children and adult never exposed to SARS-CoV-2[44] may correspond to natural antibodies. NK cells and natural antibodies contain the infection, whilst adaptive immune response develop to generate highly-specific memory T and B cells for clearing the virus and prevent re-infection[10].

In order to understand the basis of the immune response in COVID-19, we performed a global analysis of innate and adaptive immunity in patients selected across the spectrum of disease severity, ranging from SARS-CoV-2 positive asymptomatic individuals to patients with mild and severe COVID-19.

Our data show that the balance between NK cells and monocytes is a sensitive indicator of the individual reaction to the virus and is related to the clinical course of the disease. We found that when NK cells are reduced, monocytes increase. Since each individual included in our study

378 maintained typical NK and monocyte frequency throughout the time of follow-up, we utilized the
379 ratio between peripheral blood monocyte and NK cells (MNKR) as a marker reflecting the clinical
380 phenotypes of the disease.

381 In patients with severe disease, monocytes expand and secrete inflammatory cytokines[45]. At this
382 point, inflammation may get out of control and cause immunopathology manifestations, supported
383 by the observation that SARS-CoV-2 infection of respiratory epithelial cells results in aberrant
384 transcriptional responses: antiviral IFN-I and III are not induced and, instead, a consistent
385 chemokines signature is established[46]. Migration of monocytes to the infected lungs scales up
386 inflammation resulting in further tissue damage[47,48]. Most of the described immune alterations
387 are reminiscent of Hemophagocytic Lymphohistiocytosis (HLH), a condition often related to
388 mutations of genes governing the cytotoxic lymphocyte machinery, where NK-cell deficiency leads
389 to chronic expansion and activation of monocytes and causes the life-threatening condition known
390 as cytokine storm[49–52]. As a consequence, therapeutic strategies counteracting the innate
391 immune failure at earlier stages of virus infection and counteracting excessive pro-inflammatory
392 cytokine levels have been successfully used in severe COVID-19[53,54]. Not only immune
393 "suppressive, yet also immune-modulatory therapies may be advantageous, depending on the
394 immunological situation of the patients[55].

395 We measured the specific IgG and IgA response to the S1 domain of the SARS-CoV-2 spike
396 protein in the serum of all patients and controls in our study at different time points. We found that
397 the clinical phenotypes of disease correspond to different antibody responses. We confirm that the
398 highest levels of IgG and also IgA are produced by patients with severe disease relatively late
399 during hospitalization[56]. Thus, a long and severe disease activates the adaptive immune response
400 and is associated with the production of anti-SARS-CoV-2 antibodies and MBCs[57].

401 In asymptomatic patients, we show an early burst of IgA that may rapidly and effectively eliminate
402 the virus in the respiratory mucosa and prevent a full adaptive immune reaction. Accordingly, IgG
403 is produced in low amounts and becomes undetectable after 6-8 weeks. An intermediate response is
404 observed in patients with mild disease without the early IgA peak and characterized by a late, but
405 modest IgG and IgA production, suggesting a minor adaptive immune response. Further studies are
406 necessary to establish whether specific memory persist and for how long after asymptomatic and
407 mild disease.

408 The particular antigen-specific IgA/IgG profile associated with clinical outcome may reflect
409 increased TGF-beta production induced by coronavirus-species[58]. Increased viral load may
410 increase TGF-beta production, that – if produced locally in the lung, facilitates neutrophil attraction

411 and induces specifically the isotype switch to IgA[59] - a situation that prompted the suggestion of
412 anti-TGF-beta directed immunotherapies[60,61].

413 Innate MBCs are increased in asymptomatic and mild disease. Innate MBCs produce natural
414 antibodies in response to TLR stimulation[30,39] but are also able to enter the GC where they
415 remodel their antibodies to increase their affinity[28,62]. IgM^+ MBCs are the precursors of most
416 IgA^+ and IgG^+ switched MBCs[62] and give rise to IgA^+ plasma cells at mucosal site[63]. We
417 speculate that the early IgA burst of asymptomatic individuals may derive from the rapid activation
418 of pre-existing innate or cross-reactive IgM^+ MBCs that switched to IgA in the respiratory
419 mucosa[11], as suggested also be the demonstration that moderate levels of IgM and IgA cross-
420 reactive to SARS-CoV-2 are present in the blood healthy individuals never exposed to the
421 infection[44]. In agreement with our hypothesis, neutralizing IgG MBCs isolated from COVID-19
422 patients may have no or very few somatic mutations[64]. In patients with severe COVID-19, IgM^+
423 MBCs are reduced and we observed an increase of IgG^- MBCs probably expressing IgA (and thus
424 reflecting the immune reaction in the lymphoid tissue associated to the respiratory tree for local
425 protection. Circulating plasmablasts are increased only in the severe cases in correlation with their
426 high antibody levels especially of IgA isotype.

427 Our analysis of circulating T cells shows that in asymptomatic individuals, SARS-COV-2 infection
428 did not alter the T cell pool. In mild COVID-19, we only found an increase of activated $CD4^+$ T
429 cells, whereas in severe cases the activation of both $CD4^+$ and $CD8^+$ T cells might lead to clonal
430 exhaustion[5].

431 SARS-CoV-2 has evolved in bats, which control the infection through their innate immune system,
432 enriched for NK receptors and different types of INF type I genes[65]. Bats also produce antibodies
433 that are highly diverse thanks to a repertoire of VH, DH and JH fragments that is much larger than
434 that found in humans[66,67]. Antibodies do not undergo further improvement by introduction of
435 somatic mutation. Thus, constitutive IFN type I secretion and ready-to-use antibodies may control
436 viral infection in bats without the need of adaptive immune responses. For this reason,
437 coronaviruses and other viruses remain endemic in bats, without damaging the host[65].
438 Asymptomatic humans may behave like bats, controlling the infection thanks to NK cells and
439 antibodies. The adaptive immune response is strongest in patients with severe disease, following the
440 extensive tissue damage caused by the uncontrolled inflammatory reaction.

441 Our data has important implications for the control of clinical disease and for public health. In
442 COVID-19, it is indispensable to have prognostic markers early in the course of disease in order to
443 promptly choose appropriate treatments[68]. Although the MLR can be used as an indicator of
444 severe disease[69], the MNKR and the levels of specific IgA antibody in the serum may be more

445 sensible early markers of disease evolution.

446 Herd immunity to a virus is established when the large majority of the population becomes immune
447 and indirectly protects susceptible individuals. Memory T and B cells and long-lived plasma cells
448 generated by the adaptive immune response are the prerequisite for herd immunity, because specific
449 antibodies in the serum and immediately active memory cells prevent individual re-infection and
450 arrest pathogen transmission. Our data suggests that herd immunity to SARS-CoV-2 cannot be
451 achieved by natural infection. Social distancing and infection control will remain indispensable to
452 limit spread of SARS-CoV-2, until effective vaccines able to induce strong and long-lasting B- and
453 T-cell memory are available. Meanwhile, serology, especially when specific IgG is measured, may
454 be not a useful tool to support health policy measures[70]. We may fail to detect past mild
455 infections due to the rapid decline of IgG and we may under-evaluate persistence of viral circulation
456 because asymptomatic individuals respond to the virus with IgA.

457

458

459

460 **References**

461 1. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients
462 with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet **2020**;

463 2. Maggi E, Canonica GW, Moretta L. COVID-19: unanswered questions on immune response
464 and pathogenesis. J Allergy Clin Immunol **2020**; Available at:
465 http://www.sciencedirect.com/science/article/pii/S009167492030631X.

466 3. Zhao Q, Meng M, Kumar R, et al. Lymphopenia is associated with severe coronavirus
467 disease 2019 (COVID-19) infections: A systemic review and meta-analysis. Int J Infect Dis
468 **2020**;

469 4. Diao B, Wang C, Tan Y, et al. Reduction and Functional Exhaustion of T Cells in Patients
470 With Coronavirus Disease 2019 (COVID-19). Front Immunol **2020**;

471 5. Weiskopf D, Schmitz KS, Raadsen MP, et al. Phenotype of SARS-CoV-2-specific T-cells in
472 COVID-19 patients with acute respiratory distress syndrome. medRxiv **2020**; Available at:
473 https://www.medrxiv.org/content/early/2020/04/18/2020.04.11.20062349.

474 6. Long QX, Liu BZ, Deng HJ, et al. Antibody responses to SARS-CoV-2 in patients with
475 COVID-19. Nat Med **2020**;

476 7. Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-
477 19 patients. Proc Natl Acad Sci **2020**;

478 8. Okba NMA, Muller MA, Li W, et al. SARS-CoV-2 specific antibody responses in COVID-
479 19 patients. medRxiv **2020**;

480 9. Wu F, Wang A, Liu M, et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-
481 19 recovered patient cohort and their implications. medRxiv **2020**;

482 10. Kurosaki T, Kometani K, Ise W. Memory B cells. Nat Rev Immunol **2015**; 15:149–59.
483 Available at: http://www.ncbi.nlm.nih.gov/pubmed/25677494.

484 11. Padoan A, Sciacovelli L, Basso D, et al. IgA-Ab response to spike glycoprotein of SARS-
485 CoV-2 in patients with COVID-19: A longitudinal study. Clin Chim Acta **2020**;

486 12. Zhang B, Zhou X, Zhu C, et al. Immune phenotyping based on neutrophil-to-lymphocyte
487 ratio and IgG predicts disease severity and outcome for patients with COVID-19. medRxiv
488 **2020**;

489 13. Zhao J, Yuan Q, Wang H, et al. Antibody responses to SARS-CoV-2 in patients of novel
490 coronavirus disease 2019. Clin Infect Dis **2020**;

491 14. Wan Y, Shang J, Sun S, et al. Molecular Mechanism for Antibody-Dependent Enhancement
492 of Coronavirus Entry. J Virol **2019**;

493 15. He R, Lu Z, Zhang L, et al. The clinical course and its correlated immune status in COVID-
494 19 pneumonia. J Clin Virol **2020**;

495 16. Wang Y, Kang H, Liu X, Tong Z. Asymptomatic Cases with SARS-CoV-2 Infection. J Med
496 Virol **2020**; n/a. Available at: https://doi.org/10.1002/jmv.25990.

497 17. Arabi YM, Balkhy HH, Hayden FG, et al. Middle east respiratory syndrome. N Engl J Med
498 **2017**;

499 18. Bordoni V, Sacchi A, Cimini E, et al. An inflammatory profile correlates with decreased
500 frequency of cytotoxic cells in COVID-19. Clin Infect Dis **2020**; Available at:
501 https://doi.org/10.1093/cid/ciaa577.

502 19. Patel AA, Zhang Y, Fullerton JN, et al. The fate and lifespan of human monocyte subsets in
503 steady state and systemic inflammation. J Exp Med **2017**;

504 20. Wildgruber M, Aschenbrenner T, Wendorff H, et al. The 'intermediate' CD14++ CD16+
505 monocyte subset increases in severe peripheral artery disease in humans. Sci Rep **2016**;

506 21. Nockher WA, Scherberich JE. Expanded CD14+ CD16+ Monocyte subpopulation in patients
507 with acute and chronic infections undergoing hemodialysis. Infect Immun **1998**;

508 22. Narasimhan PB, Marcovecchio P, Hamers AAJ, Hedrick CC. Nonclassical Monocytes in
509 Health and Disease. Annu Rev Immunol **2019**;

510 23. Laidlaw BJ, Craft JE, Kaech SM. The multifaceted role of CD4+ T cells in CD8+ T cell
511 memory. Nat. Rev. Immunol. 2016;

512 24. Victora GD, Schwickert TA, Fooksman DR, et al. Germinal center dynamics revealed by
513 multiphoton microscopy with a photoactivatable fluorescent reporter. Cell **2010**; 143:592–
514 605.

515 25. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of
516 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet **2020**;

517 26. Zheng M, Gao Y, Wang G, et al. Functional exhaustion of antiviral lymphocytes in COVID-
518 19 patients. Cell. Mol. Immunol. 2020;

519 27. Romero P, Zippelius A, Kurth I, et al. Four Functionally Distinct Populations of Human
520 Effector-Memory CD8 + T Lymphocytes . J Immunol **2007**;

521 28. Aranburu A, Piano Mortari E, Baban A, et al. Human B-cell memory is shaped by age- and
522 tissue-specific T-independent and GC-dependent events. Eur J Immunol **2017**; 47.

523 29. Victora GD, Nussenzweig MC. Germinal Centers. Annu Rev Immunol **2011**; 30:429–457.
524 Available at: http://www.annualreviews.org/doi/abs/10.1146/annurev-immunol-020711-
525 075032%5Cnhttp://www.ncbi.nlm.nih.gov/pubmed/22224772.

526 30. Aranburu A, Ceccarelli S, Giorda E, Lasorella R, Ballatore G, Carsetti R. TLR ligation
527 triggers somatic hypermutation in transitional B cells inducing the generation of IgM
528 memory B cells. J Immunol **2010**; 185:7293–7301.

529 31. Capolunghi F, Rosado MM, Sinibaldi M, Aranburu A, Carsetti R. Why do we need IgM
530 memory B cells? Immunol. Lett. 2013; 152:114–120.

531 32. Yu H, Sun B, Fang Z, et al. Distinct features of SARS-CoV-2-specific IgA response in
532 COVID-19 patients. Eur Respir J **2020**;

533 33. Lam VC, Lanier LL. NK cells in host responses to viral infections. Curr. Opin. Immunol.
534 2017;

535 34. Vidal SM, Khakoo SI, Biron CA. Natural killer cell responses during viral infections:
536 Flexibility and conditioning of innate immunity by experience. Curr. Opin. Virol. 2011;

537 35. Abel AM, Yang C, Thakar MS, Malarkannan S. Natural killer cells: Development,
538 maturation, and clinical utilization. Front. Immunol. 2018;

539 36. Ochsenbein AF, Zinkernagel RM. Natural antibodies and complement link innate and
540 acquired immunity. Immunol. Today. 2000;

541 37. Ochsenbein AF, Fehr T, Lutz C, et al. Control of early viral and bacterial distribution and
542 disease by natural antibodies. Science (80-) **1999**;

543 38. Kang S, Brown HM, Hwang S. Direct antiviral mechanisms of interferon-gamma. Immune
544 Netw. 2018;

545 39. Capolunghi F, Cascioli S, Giorda E, et al. CpG drives human transitional B cells to terminal
546 differentiation and production of natural antibodies. J Immunol **2008**; 180:800–808.

547 40. Rosado MM, Aranburu A, Capolunghi F, et al. From the fetal liver to spleen and gut: the
548 highway to natural antibody. Mucosal Immunol **2009**; 2:351–361. Available at:
549 http://www.ncbi.nlm.nih.gov/pubmed/19421184.

550 41. Holodick NE, Rodríguez-Zhurbenko N, Hernández AM. Defining Natural Antibodies. Front
551 Immunol **2017**; 8:872.

552 42. Throsby M, van den Brink E, Jongeneelen M, et al. Heterosubtypic neutralizing monoclonal
553 antibodies cross-protective against H5N1 and H1N1 recovered from human IgM^+ memory B
554 cells. PLoS One **2008**; 3.

555 43. Carsetti R, Quintarelli C, Quinti I, et al. The immune system of children: the key to
556 understanding SARS-CoV-2 susceptibility? Lancet Child Adolesc Heal **2020**; 4:414–416.
557 Available at: https://doi.org/10.1016/S2352-4642(20)30135-8.

558 44. Selva KJ, Sandt CE van de, Lemke MM, et al. Distinct systems serology features in children,
559 elderly and COVID patients. medRxiv **2020**;

560 45. Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for

561 monocytes and macrophages. Nat Rev Immunol **2020**; Available at:
562 https://doi.org/10.1038/s41577-020-0331-4.

563 46. Blanco-Melo D, Nilsson-Payant BE, Liu WC, et al. Imbalanced Host Response to SARS-
564 CoV-2 Drives Development of COVID-19. Cell **2020**;

565 47. McGonagle D, Sharif K, O'Regan A, Bridgewood C. The Role of Cytokines including
566 Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like
567 Disease. Autoimmun. Rev. 2020;

568 48. Sanchez-Cerrillo I, Landete P, Aldave B, et al. Differential Redistribution of Activated
569 Monocyte and Dendritic Cell Subsets to the Lung Associates with Severity of COVID-19.
570 medRxiv **2020**;

571 49. Prilutskiy A, Kritselis M, Shevtsov A, et al. SARS-CoV-2 Infection Associated
572 Hemophagocytic Lymphohistiocytosis: An autopsy series with clinical and laboratory
573 correlation. medRxiv **2020**;

574 50. Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science (80-) **2020**;

575 51. Hayden A, Park S, Giustini D, Lee AYY, Chen LYC. Hemophagocytic syndromes (HPSs)
576 including hemophagocytic lymphohistiocytosis (HLH) in adults: A systematic scoping
577 review. Blood Rev. 2016;

578 52. Locatelli F, Jordan MB, Allen C, et al. Emapalumab in Children with Primary
579 Hemophagocytic Lymphohistiocytosis. N Engl J Med **2020**;

580 53. Zhang S, Li L, Shen A, Chen Y, Qi Z. Rational Use of Tocilizumab in the Treatment of
581 Novel Coronavirus Pneumonia. Clin. Drug Investig. 2020;

582 54. King A, Vail A, O'Leary C, et al. Anakinra in COVID-19: important considerations for
583 clinical trials. Lancet Rheumatol **2020**; Available at: https://doi.org/10.1016/S2665-
584 9913(20)30160-0.

585 55. Hung IF-N, Lung K-C, Tso EY-K, et al. Triple combination of interferon beta-1b, lopinavir–
586 ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an
587 open-label, randomised, phase 2 trial. Lancet **2020**;

588 56. Dahlke C, Heidepriem J, Kobbe R, et al. Distinct early IgA profile may determine severity of
589 COVID-19 symptoms: an immunological case series. medRxiv **2020**;

590 57. Andreano E, Nicastri E, Paciello I, et al. Identification of neutralizing human monoclonal
591 antibodies from Italian Covid-19 convalescent patients. bioRxiv **2020**;

592 58. He L, Ding Y, Zhang Q, et al. Expression of elevated levels of pro-inflammatory cytokines in
593 SARS-CoV-infected ACE2+ cells in SARS patients: Relation to the acute lung injury and
594 pathogenesis of SARS. J Pathol **2006**;

595 59. Stavnezer J, Kang J. The Surprising Discovery That TGFβ Specifically Induces the IgA
596 Class Switch. J Immunol **2009**;

597 60. Chen W. A potential treatment of COVID-19 with TGF-β blockade. Int. J. Biol. Sci. 2020;

598 61. Ferner RE, Aronson JK. Remdesivir in covid-19. BMJ. 2020;

599 62. Grimsholm O, Piano Mortari E, Davydov AN, et al. The Interplay between CD27dull and
600 CD27bright B Cells Ensures the Flexibility, Stability, and Resilience of Human B Cell

601 Memory. Cell Rep **2020**;

602 63. Carsetti R, Di Sabatino A, Rosado MM, et al. Lack of Gut Secretory Immunoglobulin A in
603 Memory B-Cell Dysfunction-Associated Disorders: A Possible Gut-Spleen Axis. Front
604 Immunol **2020**;

605 64. Seydoux E, Homad LJ, MacCamy AJ, et al. Analysis of a SARS-CoV-2 infected individual
606 reveals development of potent neutralizing antibodies to distinct epitopes with limited
607 somatic mutation. Immunity **2020**; Available at:
608 http://www.sciencedirect.com/science/article/pii/S1074761320302314.

609 65. Pavlovich SS, Lovett SP, Koroleva G, et al. The Egyptian Rousette Genome Reveals
610 Unexpected Features of Bat Antiviral Immunity. Cell **2018**;

611 66. Baker ML, Tachedjian M, Wang LF. Immunoglobulin heavy chain diversity in Pteropid bats:
612 Evidence for a diverse and highly specific antigen binding repertoire. Immunogenetics **2010**;

613 67. Banerjee A, Baker ML, Kulcsar K, Misra V, Plowright R, Mossman K. Novel Insights Into
614 Immune Systems of Bats. Front. Immunol. 2020;

615 68. chen meizhu, tu changli, Tan C, et al. Key to successful treatment of COVID-19: accurate
616 identification of severe risks and early intervention of disease progression. medRxiv **2020**;

617 69. Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with COVID-19 in
618 Wuhan, China. Clin Infect Dis **2020**;

619 70. Weinstein MC, Freedberg KA, Hyle EP, Paltiel AD. Waiting for Certainty on Covid-19
620 Antibody Tests — At What Cost? N Engl J Med 0:null. Available at:
621 https://doi.org/10.1056/NEJMp2017739.

622

623

Figure



Figure 1

Figure 1: (a) Flow-cytometry analysis of the monocyte to lymphocyte ratio (MLR) in the blood of three representative patients with asymptomatic, mild and severe disease. The lympho-monocyte gate was designed based on physical characteristics (FSC-A vs SSC-A). Lymphocytes were gated as FSC-A^{low} and $CD3^{+}$ or $CD3^{-}$ and monocytes as $CD3^{-}$ FSC-A^{high}. (b) Scatter plot depicts the MLR in the sixty-four adult patients enrolled in the study (contacts *n=28*; asymptomatic *n=20*; mild *n=8*; severe *n=8*). (c) Gating strategy used to identify natural killer (NK) and monocytes inside the $CD3^{-}$ cells in three representative patients with asymptomatic, mild and severe disease. NK cells were defined as $CD3^{-}CD7^{+}$FSC-A^{low} and monocytes as $CD3^{-}CD7^{-}$FSC-A^{high}. (d) Heatmaps of the percentage of NK and monocytes in contacts (indicated by the light green bar), asymptomatic (blue), mild (orange) and severe (red) patients. Percentage levels are reported as differential expression of color. (e) Plots indicate the frequency of NK, monocytes and the monocytes/NK ratio (MNKR) in our patients. (b and e) Midlines indicate mean. Statistical significances were determined using unpaired, two-tailed Mann-Whitney *U*-tests. *$p \leq 0.05$, **$p < 0.01$, ***$p < 0.001$.



Figure 2

Figure 2: (a) Plots indicate the frequency of NK, monocytes and MNKR ratio in all analyzed samples. We show here all the results, including also those relative to multiple samples of the same patients collected at different time points.

645 (b) Heatmaps show the percentage of NK and monocytes in asymptomatic, mild and severe patients (Pt) measured at
646 different time points. Percentage levels are reported as differential expression of red, blue and white. (c) Plot shows the
647 percentage of NK cells in non-ICU (*n=43*) and ICU (*n=34*) patients. (d) Graphs show the evolution over time of NK
648 cells percentage in patients with favorable and fatal outcome. (a and c) Midlines indicate mean. Statistical significances
649 were determined using unpaired, two-tailed Mann-Whitney *U*-tests. *p≤0.05, **p<0.01, ***p<0.001.
650



651
652 **Figure 3:** (a) FACS plots depict the gating strategy to identify $CD3^+$, $CD3^+CD4^+$, $CD3^+CD8^+$ T cells in three
653 representative patients (asymptomatic, mild and severe). HLA-DR expression in $CD4^+$ or $CD8^+$ T cells is shown in the
654 relative plots. Frequency of HLA-DR^+ cells are reported in the plots. (b) Plots show the percentage of $CD3^+$, $CD4^+$,
655 $CD8^+$ and HLA-DR^+ T cells as single value. Mean is shown as midline. Statistical significances were determined using
656 unpaired, two-tailed Mann-Whitney *U*-tests. *p≤0.05, **p<0.01, ***p<0.001.
657



Figure 4

Figure 4: (a-b) Results obtained by the analysis of CD4$^+$ (Plots a) and CD8$^+$ T cells (Plots b) are separately shown. Graphs show the percentage of *naïve* T cells (CD3$^+$CCR7$^+$CD45RA$^+$) that either expressed or lack CD31 (CD31$^+$ are

662 recent thymic emigrants and $CD31^-$ are revertant T cells). Effector memory T cells ($CD3^+CCR7^-CD45RA^-$) can be
663 separated in EM1, EM2, EM3 and EM4. TEMRA T cells are $CD3^+CCR7^-CD45RA^+$. Midlines indicate mean. Statistical
664 significances were determined using unpaired, two-tailed Mann-Whitney *U*-tests. *$p \leq 0.05$, **$p < 0.01$, ***$p < 0.001$.
665



Figure 5

Figure 5: (a) Viable lymphocytes were gated and then selected as CD19^{+} B cells in three representative patients with asymptomatic, mild and severe disease. The identification of the different B cell populations is shown in the empty

670 plots of the upper line. We identified transitional ($CD24^{+}CD38^{++}$), naïve ($CD24^{+}CD27^{-}$), memory ($CD24^{+}CD27^{+}$),
671 atypical MBCs ($CD24^{-}CD38^{-}$) and plasmablasts ($CD24^{-}CD27^{++}CD38^{++}$). In the $CD27^{+}$ memory B-cell population based
672 on IgM expression, we show IgM and switched (IgM^{-}) MBCs. MBCs were also gated as IgM^{+}, IgG^{+} and $IgG^{-}IgM^{-}$
673 MBCs. (b) Plots indicates the percentage of B cells, MBCs and plasmablasts. In c the frequencies of IgM and switched
674 MBCs is show. Panel d we show the frequency of IgG^{+}, $IgG^{-}IgM^{-}$MBCs. The ratio between IgG^{+} and $IgG^{-}IgM^{-}$ is also
675 shown. Midlines indicate mean. Statistical significances were determined using unpaired, two-tailed Mann-Whitney *U*-
676 tests. *$p \leq 0.05$, **$p<0.01$, ***$p<0.001$.
677
678



Figure 6

Figure 6: (a) IgG and IgA specific for the S1 domain of the SARS-CoV-2 Spike protein were detected by an ELISA method at different time points and concentrations are shown in arbitrary units (AU). Data relative to all samples are shown. Midlines indicate mean. Statistical significances were determined using unpaired, two-tailed Mann-Whitney *U*-

683 tests. *$p \leq 0.05$, **$p < 0.01$, ***$p < 0.001$. (b-d) Graphs show the levels (AU) of IgA (solid line) and IgG (dashed line)
684 during the course of the disease in three asymptomatic (b), three mild (c) and three severe (d) disease patients. (e)
685 Kinetics of antibody titers in asymptomatic patients. Time is indicated in weeks from the first positive nasopharyngeal
686 swab. Empty circles represent patients of which we had only one sample and antibodies were undetectable.
687
688
689
690
691
692
693